Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease: A single‐centre experience

Abstract

Improvement of life expectancy in patients with haemophilia A (HA), haemophilia B (HB) and von Willebrand disease (VWD) has led to a rising of age-related comorbidities, specifically coronary artery disease. The safety and efficacy of antiplatelet drugs for patients with inherited bleeding disorders remain unclear, and there are currently no evidence-based guidelines for the antithrombotic management in this population. Our study objectives were to describe the management of patients with HA, HB and VWD and the occurrence of ischaemic heart disease in our Inherited Bleeding Disorders (IBD) referral centre at the University Hospital of Toulouse, in the Occitania administrative region of metropolitan France, to compare this management to experts recommendations published between 2013 and 2016,1-3 and to evaluate the safety and the efficacy of antiplatelet drugs, including aspirin and clopidogrel, in this patient population. Our population was identified from the 2008-2018 cohort of HA (n = 565), HB (n = 115) and VWD (n = 618) patients followed at the Toulouse University Hospital, France. We retrospectively identified patients who had experienced an ischaemic heart disease treated